Branded

Janssen's Invokana has received the Food and Drug Administration's blessing, making it the first oral diabetes treatment approved for cardiovascular events.

Jazz Pharmaceuticals' FDA approval of a new indication for Xyrem gives narcolepsy patients age seven years old and older a treatment for cataplexy, or excessive daytime sleepiness,

Mayne Pharma is planning to launch halobetasol foam, a potent corticosteroid for plaque psoriasis, in early 2019.

Xofluza is the first new antiviral flu treatment with a novel mechanism of action approved by the Food and Drug Administration in nearly 20 years.

Spectrum Pharmaceuticals' Khapzory for injection is the first Food and Drug Administration approved levoleucovorin product that contains sodium.

Sun Pharma is introducing its Ilumya injectable, which has been approved by the Food and Drug Administration, for the treatment of moderate-to-severe plaque psoriasis in adults.

The FDA's approval of Regeneron and Sanofi's Dupixent provides patients with moderate-to-severe asthma, age 12 years old and older, with a new treatment option.

Fresenius Kabi is offering the first FDA-approved prefilled delivery system for palonosetron hydrochloride injection for cancer patients.